Oo TT, Storch V, Madon MB, Becker N
Targets specific areas of damage including muscles, tendons, ligaments, and the gut
Although all unimolecular triple agonists in phase 2 trials for obesity are GLP1/GIP/GCG triple agonists, there is an ongoing phase 2 clinical trial of bioglutide, an oral insulin-like-growth factor-1 (IGF-1)/GLP-1/GIP/GCG quadruple agonist (NCT06564753) for individuals with obesity, which is also being trialled in combination with tirzepatide (NCT06643728)
doi: 10.1038/nm919 31 SalcedoITweedieDLiYGreigNH
Once the shot is logged and the curve is understood, the user still has to live the next few days: meals, protein, water, symptoms, energy, digestion, progress photos, weight changes, and the small decisions that make the journey easier or harder